Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators
Tegoprazan is a novel potassium-competitive acid blocker (P-CAB) developed by CJ Healthcare (Korea) for the treatment of gastroesophageal reflux disease and helicobacter pylori infections. Tegoprazan is mainly metabolized by cytochrome P450 (CYP) 3A4. Considering the therapeutic indications, tegopra...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2023-01-01
|
| Col·lecció: | Pharmaceutics |
| Matèries: | |
| Accés en línia: | https://www.mdpi.com/1999-4923/15/1/182 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|